1. Cross Talk between COVID-19 and Breast Cancer
   Hamendra Singh Parmar et al, 2021, Current Cancer Drug Targets CrossRef
2. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
   Shahad Sabaawi Ibrahim et al, 2024, Cancer and Metastasis Reviews CrossRef
3. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
   Stav Brown et al, 2024, Frontiers in Pharmacology CrossRef
4. Bioinformatic Searching for Optimal RNA Targets of Dimeric Compounds Informs Design of a MicroRNA-27a Inhibitor
   Raphael I. Benhamou et al, 2022, ACS Chemical Biology CrossRef
5. GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
   Fionnuala Crowley et al, 2024, Frontiers in Oncology CrossRef
6. MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations
   Jingcheng Zhang et al, 2019, Frontiers in Oncology CrossRef
7. Onkodiabetológia II.
   Róbert János Bánhegyi et al, 2022, Orvosi Hetilap CrossRef
8. Anti-Obesity Medications in Cancer Therapy: A Comprehensive Insight
   Rajveer Shekhawat et al, 2021, Current Cancer Drug Targets CrossRef
9. Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
   Young-Gyun Seo, 2021, Journal of Obesity & Metabolic Syndrome CrossRef
10. Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity
    Marina Caputo et al, 2021, Frontiers in Endocrinology CrossRef
11. Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy
    Pamela Soberanis Pina et al, 2024, Biologics: Targets and Therapy CrossRef